Lymphoid Tyrosine Phosphatase Gene Polymorphisms in Inflammatory Bowel Disease
1 other identifier
observational
200
0 countries
N/A
Brief Summary
This study aims:
- 1.To investigate the association between single nucleotide polymorphisms of PTPN22 gene (rs2476601, rs33996649 and rs2488457) and inflammatory bowel disease.
- 2.To correlate the relation between the studied SNPs and disease activity /response to therapy.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started May 2020
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
February 23, 2020
CompletedFirst Posted
Study publicly available on registry
February 26, 2020
CompletedStudy Start
First participant enrolled
May 1, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 1, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
September 1, 2021
CompletedFebruary 26, 2020
February 1, 2020
1 year
February 23, 2020
February 25, 2020
Conditions
Outcome Measures
Primary Outcomes (1)
Association between single nucleotide polymorphisms of Lymphoid Tyrosine Phosphatase gene (rs2476601, rs33996649 and rs2488457) and inflammatory bowel disease
Three single nucleotide polymorphisms in the lymphoid tyrosine phosphatase gene(SNP (G788\>A) in exon10, SNP (C1858\>T) in exon 14 and SNP (G -1123\>C) in the promoter region ) will be assessed in 100 patients diagnosed as inflammatory bowel disease and 100 healthy subjects by Polymerase Chain Reaction-Restriction Fragment Length Polymorphism (PCR-RFLP) to detect association between these polymorphisms and inflammatory bowel disease
baseline
Secondary Outcomes (1)
To correlate the relation between the studied SNPs and disease activity /response to therapy.
baseline
Study Arms (2)
A
patients with inflammatory bowel disease
B
healthy subjects
Interventions
Eligibility Criteria
IBD Patients will Diagnosed according to established guidelines for UC/CD . Phenotype characteristics of UC and CD were defined according to the Montreal classification . The clinical disease activity will be assessed using the Montreal classification of UC disease activity and Crohn's Disease Activity Index (CDAI) for CD
You may qualify if:
- patients with inflammatory bowel disease
You may not qualify if:
- Patients with systemic autoimmune diseases (RA,SLE) will be excluded from the study .
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Related Publications (1)
Norouzinia M, Chaleshi V, Alizadeh AHM, Zali MR. Biomarkers in inflammatory bowel diseases: insight into diagnosis, prognosis and treatment. Gastroenterol Hepatol Bed Bench. 2017 Summer;10(3):155-167.
PMID: 29118930BACKGROUND
Biospecimen
gene polymorphisms
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- doctor
Study Record Dates
First Submitted
February 23, 2020
First Posted
February 26, 2020
Study Start
May 1, 2020
Primary Completion
May 1, 2021
Study Completion
September 1, 2021
Last Updated
February 26, 2020
Record last verified: 2020-02
Data Sharing
- IPD Sharing
- Will not share